

# Wen Wee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/430483/publications.pdf>

Version: 2024-02-01

11  
papers

312  
citations

1684188

5  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

409  
citing authors

#	ARTICLE	IF	CITATIONS
1	Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2020, 6, e204930.	7.1	124
2	Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5- <i>fluorouracil</i> and capecitabine toxicity. <i>Cancer</i> , 2017, 123, 345-356.	4.1	91
3	Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction. <i>Clinical Cancer Research</i> , 2022, 28, 3021-3031.	7.0	32
4	The role of microbiome in pancreatic cancer. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 777-789.	5.9	27
5	Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. <i>Journal of Gastrointestinal Oncology</i> , 2013, 4, 231-8.	1.4	18
6	Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. <i>Oncologist</i> , 2020, 25, e1681-e1690.	3.7	5
7	Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. <i>Pancreatology</i> , 2021, 21, 379-383.	1.1	5
8	A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 7-17.	2.3	5
9	A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 779-788.	2.3	3
10	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	3.0	2
11	Reply to A. Rizzo et al. <i>JCO Precision Oncology</i> , 2022, 6, e2200061.	3.0	0